Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595462 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL5065108 | 0.88 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL5065109 | 0.88 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL691440 | 0.73 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL691439 | 0.73 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL5062800 | 0.65 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL5062797 | 0.65 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL4595536 | 0.61 | RPS6KA5 (0.69) | — | |
| SCHEMBL5597279 | 0.61 | ALDH1A1 (0.34) | SMN1; SMN2ALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL4596427 | 0.60 | RORC (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | SMN1; SMN2 3299/4885ALDH1A1 4166/4885HPGD 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.